Clinical trials: Type 1 and 2 Diabetes
Patients
Drug Interaction Study Between Dorzagliatin and Empagliflozin
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM.
- Trial name
- NCT03790787
- Testing
- Empagliflozin, Dorzagliatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hua Medicine Limited
Type I Diabetes
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
- Trial name
- NCT06964087
- Testing
- OPT101
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Op-T LLC
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
FDC, Diabetes Mellitus, Type 2
To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination
To compare the safety and pharmacokinetic properties between the administration of DWP16001 and DWC202213 as an individual drug, and the administration of DWJ1563 as a combination drug.
- Trial name
- NCT05737771
- Testing
- DWC202213, DWJ1563, DWP16001
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 1 Diabetes Mellitus
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
The purpose of this study is to evaluate consistency of accelerated insulin absorption and onset-of-action and shortened duration of action for bolus insulin infusions after pretreatment with 150 units (U) of Hylenex®…
- Trial name
- NCT01526733
- Testing
- Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Halozyme Therapeutics
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.
- Conditions
- Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
- Trial name
- NCT00044408
- Testing
- Ruboxistaurin mesylate
- Where
- 35 sites in United States, Canada and 6 more
- Volunteers
- 200 people
- Sponsor
- Chromaderm, Inc.
Type 1 Diabetes Mellitus
Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)
The purpose of this pilot study is to evaluate performance of the SEVEN System and the Navigator System when both devices are worn concurrently by subjects with type 1 diabetes mellitus.
- Trial name
- NCT00939289
- Testing
- Continuous Glucose Monitoring
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- DexCom, Inc.
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
A randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus (T1DM)
- Trial name
- NCT03895697
- Testing
- dasiglucagon
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes Mellitus
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers
This is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-383 in healthy volunteers
- Trial name
- NCT06492655
- Testing
- CKD-383(Fed), CKD-383(Fasted)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily…
- Trial name
- MODIUS (NCT07599982)
- Testing
- MODI Algorithm
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- DreaMed Diabetes
Diabetes Type I, Diabetes Type II
Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment
The purpose of this clinical trial is to perform a limited pilot study to determine the safety and feasibility of DermGEN in the treatment of non-healing diabetic foot ulcers (DFU). This will be a one-arm prospective study.
- Trial name
- NCT02184455
- Testing
- DermGEN
- Where
- 2 sites in Canada
- Volunteers
- 11 people
- Sponsor
- Dr. Paul F. Gratzer
Healthy, Prediabetic State (IGT)
Noninvasive Transcutaneous Glucometer Development
The objective of this study is to assist in the development of a noninvasive device for the accurate measurement of blood glucose levels.
- Conditions
- Healthy, Prediabetic State (IGT), Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT01168076
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- InLight Solutions
Diabetes Mellitus, Type 1
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes.
- Trial name
- ONWARDS 6 (NCT04848480)
- Testing
- insulin icodec, insulin degludec, insulin aspart
- Where
- 130 sites in United States, Austria and 10 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects
PF 04603629 is a long acting exendin proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and glucose lowering capabilities following a…
- Trial name
- NCT00638313
- Testing
- PF-04603629
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 1
Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period
This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01900834
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial
This trial is conducted in Europe. The aim of the trial is to compare two methods of injection in basal-bolus insulin regimen in children with type 1 diabetes with insulin detemir associated with insulin aspart given twice daily…
- Trial name
- MIXING (NCT00542620)
- Testing
- insulin detemir, insulin aspart
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India
This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare India (NCT01351922)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 12,000 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Type 1 Diabetes
European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.
Accu-Chek® Insight Insulin Pump EU Study is a Multicenter Study to evaluate the Accu-Chek® Insight Insulin Pump in routine practice.
- Trial name
- NCT02105103
- Testing
- Accu-Chek® Insight Insulin Pump
- Where
- 8 sites in Austria, United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Diabetes Mellitus, Type 2
Single Dose Study of PF-04991532 in Healthy Subjects
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK) and preliminary food effect of PF-04991532 following single escalating oral doses in healthy adult subjects.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Trial name
- NCT01102673
- Testing
- PF-04991532
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer